Latest news and press releases about BioXcel Therapeutics, Inc. (BTAI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology.
Price
| Price | $0.07 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.01 |
| EV / EBITDA | -1.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 69.92% |
| Return on Invested Capital | 1144.58% |
| Return on Assets | -246.05% |
| Gross Margin | 45.28% |
| Operating Margin | -6014.42% |
| Net Margin | -9549.87% |
Related companies: ANVS · BCAB · CELU · EVAX · GBIO · MAIA · MURA
Explore sector: Healthcare · Biotechnology
More sections of BTAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks